Increased levels of angiopoietin-2 in induced sputum from smoking asthmatic patients
Article first published online: 28 APR 2009
© 2009 Blackwell Publishing Ltd
Clinical & Experimental Allergy
Volume 39, Issue 9, pages 1330–1337, September 2009
How to Cite
Kanazawa, H., Asai, K., Tochino, Y., Kyoh, S., Kodama, T. and Hirata, K. (2009), Increased levels of angiopoietin-2 in induced sputum from smoking asthmatic patients. Clinical & Experimental Allergy, 39: 1330–1337. doi: 10.1111/j.1365-2222.2009.03262.x
- Issue published online: 5 AUG 2009
- Article first published online: 28 APR 2009
- Submitted 17 September 2008; revised 30 December 2008; accepted 3 March 2009
- bronchial asthma;
- cigarette smoking;
- inhaled corticosteroid therapy
Background Active cigarette smoking has detrimental effects on asthma morbidity and severity. Angiopoietin-1 has been shown to protect the microvessels against plasma leakage, whereas angiopoietin-2 enhances vascular permeability and subsequently induces airway mucosal oedema. Therefore, it is recently thought that angiopoietin-2 may contribute to the pathophysiology of asthma.
Objective To determine whether angiopoietin-2 levels in the airways are associated with clinical profiles in smoking asthmatics.
Methods We measured angiopoietin-1 and -2 levels in induced sputum in 35 normal controls (18 non-smokers and 17 smokers) and 49 asthmatics (24 non-smokers and 25 smokers) before and after inhaled beclomethasone dipropionate (BDP: 800 μg/day) therapy for 12 weeks.
Results Angiopoietin-1 and -2 levels in induced sputum were significantly higher in asthmatics than in normal controls. Moreover, angiopoietin-2 levels were significantly higher in smoking asthmatics than in non-smoking asthmatics (P=0.0001). The airway vascular permeability index was also higher in smoking asthmatics than in non-smoking asthmatics. Moreover, the angiopoietin-2 level was positively correlated with the airway vascular permeability index (non-smoking asthmatics: r=0.87, P<0.001, smoking asthmatics: r=0.64, P=0.002). After BDP therapy, angiopoietin-1 levels were significantly decreased in non-smoking asthmatics, smoking-cessation asthmatics, and active-smoking asthmatics. In contrast, angiopoietin-2 levels did not differ from before to after BDP therapy in non-smoking asthmatics and active-smoking asthmatics. However, its levels were significantly decreased from before to after BDP therapy in smoking-cessation asthmatics (P=0.002). Although forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) before BDP therapy was comparable in all subgroups, this parameter after BDP therapy was significantly lower in active-smoking asthmatics than in non-smoking and smoking-cessation asthmatics. Moreover, the reduction in angiopoietin-2 levels after BDP therapy in smoking-cessation asthmatics was significantly correlated with an mprovement in FEV1/FVC.
Conclusion Angiopoietin-2 levels were elevated in the airways of smoking asthmatics, and its levels were associated with impaired airway responses.